All News

22 August 2024

China’s First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of ChinaSmall Molecules

22 August 2024

Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular CarcinomaAntibodies

22 August 2024

D&D Pharmatech Announces Initiation of Dosing in a Phase 2 Trial Designed to Evaluate the Efficacy and Safety of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist in Overweight/Obese Subjects with MASLD/MASHProteins and Peptides

22 August 2024

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosingProteins and Peptides

21 August 2024

Regeneron Provides Update on Biologics License Application for LinvoseltamabAntibodies

21 August 2024

Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Second NDA Accepted by NPMA, locally advanced or metastatic EGFR-mutant NSCLCAntibodies

21 August 2024

IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 AgonistSmall Molecules

21 August 2024

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton SyndromeDNA RNA and Cells

21 August 2024

Innovo Therapeutics Inc. Announces Phase 2 Clinical Results Demonstrating the Innovative Efficacy of INV-001 for the Treatment of Post-thyroidectomy ScarsSmall Molecules

21 August 2024

Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweightProteins and Peptides

21 August 2024

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancerAntibodies

20 August 2024

Adcendo ApS and Multitude Therapeutics Inc. Announce Global Development and Commercialization Agreement on First-in-class ADC Drug Candidate Targeting Tissue FactorAntibodies

20 August 2024

Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic CancerAntibodies

20 August 2024

China’s National Medical Products Administration (NMPA) Approves PADCEV™ (enfortumab vedotin) for Treatment of Locally Advanced or Metastatic Urothelial CancerAntibodies

20 August 2024

TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaAntibodies

20 August 2024

Lift of Partial Clinical Hold for BNT326/YL202Antibodies

19 August 2024

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG990, its Novel Half-Life Extended OX40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesAntibodies

19 August 2024

ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301Small Molecules

19 August 2024

GlycoNex Successfully Completes Phase 1 Study of Denosumab Biosimilar, SPD8Antibodies

19 August 2024

TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerAntibodies

19 August 2024

European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular LymphomaDNA RNA and Cells

19 August 2024

MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase InhibitorSmall Molecules

19 August 2024

Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247More News

19 August 2024

Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 StudySmall Molecules

19 August 2024

ENHERTU® Type II Variation Application Validated by EMA for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following At Least One Endocrine TherapyAntibodies

18 August 2024

Bavarian Nordic Provides Statement on Mpox Vaccine Supply and Collaboration with African and Global StakeholdersVaccines

16 August 2024

Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of AgeVaccines

16 August 2024

BITT Announced CD40 Otsuka Research and Exclusivity Agreement and New NIH Funding for TNFR2 Clinical TrialAntibodies

16 August 2024

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular LymphomaAntibodies

16 August 2024

Imfinzi approved in the US for the treatment of resectable non-small cell lung cancer before and after surgeryAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

TSLP Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Blockbuster Biologics 2017: Sales of Recombinant Therapeutic Antibodies & Proteins

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review